New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome

Current Opinion in Pediatrics

Volumn 24, Issue 1, 2012, Pages 1-8

  Teachey, David T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

autoimmune lymphoproliferative syndrome; cytopenias; Evans syndrome; FAS; mTOR; RAS; secondary malignancy

Indexed keywords

FAS ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB;

ALGORITHM; ANTIGEN EXPRESSION; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; COMMON VARIABLE IMMUNODEFICIENCY; COMORBIDITY; CYTOPENIA; GENE EXPRESSION; HAPLOINSUFFICIENCY; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LYMPHADENOPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SPLENOMEGALY;

ANTIGENS, CD95; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHATIC DISEASES; MALE; MYCOPHENOLIC ACID; SIGNAL TRANSDUCTION; SIROLIMUS; SPLENOMEGALY;

EID: 84856097321     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834ea739     Document Type: Review

References (58)

1. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ 2003; 10:124-133. (Pubitemid 36511838)
2. Nagata S, Golstein P. The Fas death factor. Science 1995; 267:1449-1456.
3. Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/ autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest 1992; 90:334-341.
4. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81:935-946.
5. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268:1347-1349.
6. Bleesing JJ. Autoimmune lymphoproliferative syndrome: a genetic disorder of abnormal lymphocyte apoptosis. Immunol Allergy Clin North Am 2002; 22:339-349.
7. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010; 116:e35-e40. This article is an international consensus statement from experts in ALPS that defines a new diagnostic algorithm for ALPS and revises the nomenclature.
8. Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol 2010; 148:205-216.
9. Kuehn HS, Caminha I, Niemela JE, et al. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome. J Immunol 2011; 186:6035-6043. This article establishes that FAS haploinsufficiency is an important disease mechanism in ALPS.
10. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet 1999; 64:1002-1014. (Pubitemid 30463031)
11. Rieux-Laucat F, Blachere S, Danielan S, et al. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood 1999; 94:2575-2582. (Pubitemid 29477285)
12. Ohga S, Nomura A, Takahata Y, et al. Dominant expression of interleukin 10 but not interferon gamma in CD4(-)CD8(-)alphabetaT cells of autoimmune lymphoproliferative syndrome. Br J Haematol 2002; 119:535-538. (Pubitemid 35365510)
13. Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4-CD8-TCR alpha/beta T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood 2009; 113:3027-3030. This article provides evidence that biomarkers can be used to predict ALPS.
14. Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 2004; 351:1409-1418. (Pubitemid 39288167)
15. Straus SE, Sneller M, Lenardo MJ, et al. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 1999; 130:591-601. (Pubitemid 29169388)
16. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98:194-200.
17. Magerus-Chatinet A, Neven B, Stolzenberg MC, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest 2011; 121:106-112. This article establishes that a combination of multiple mutations (acquired and inherited) in ALPS causative genes may help explain low disease penetrance in families.
18. Van der Werff ten Bosch J. Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management. Paediatr Drugs 2003; 5:185-193.
19. Bleesing JJ. Autoimmune lymphoproliferative syndrome (ALPS). Curr Pharm Des 2003; 9:265-278.
20. Wei A, Cowie T. Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS72 T>C) affecting the Fas gene. Eur J Haematol 2007; 79:363-366. (Pubitemid 47390134)
21. Jackson CE, Puck JM. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr 1999; 11:521-527.
22. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997; 89:1341-1348. (Pubitemid 27079998)
23. Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 2006; 133:124-140.
24. Poppema S, Maggio E, van den Berg A. Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma 2004; 45:423-431. (Pubitemid 38196023)
25. Rao VK, Carrasquillo JA, Dale JK, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol 2006; 81:81-85. (Pubitemid 43208594)
26. Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005; 105:2443-2448. (Pubitemid 40387044)
27. Sneller MC, Dale JK, Straus SE. Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol 2003; 15:417-421. (Pubitemid 36774253)
28. Caminha I, Fleisher TA, Hornung RL, et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 2010; 125:946- 949, e946. This article provides evidence that biomarkers can predict ALPS.
29. Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multiinstitutional study. Blood 2010; 115:2142-2145. This article demonstrates that ALPS is underdiagnosed, as patients with presumed idiopathic autoimmune cytopenia syndromes may have ALPS.
30. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419:395-399.
31. Maric I, Pittaluga S, Dale JK, et al. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol 2005; 29:903-911. (Pubitemid 40885013)
32. Snow AL, Marsh RA, Krummey SM, et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest 2009; 119:2976-2989.
33. Niemela JE, Lu L, Fleisher TA, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 2010; 117:2883-2886.
34. Oliveira JB, Bidere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA 2007; 104:8953-8958. (Pubitemid 47175418)
35. Takagi M, Shinoda K, Piao J, et al. Autoimmune lymphoproliferative syndromelike disease with somatic KRAS mutation. Blood 2010; 117:2887-2890.
36. Savasan S, Warrier I, Buck S, et al. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans' syndrome. Clin Immunol 2007; 125:224-229. (Pubitemid 350116712)
37. Evans RS, Takahashi K, Duane RT, et al. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med 1951; 87:48-65.
38. Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica 2011; 96:655-663.
39. Bleesing JJ, Straus SE, Fleisher TA. Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 2000; 47:1291-1310. (Pubitemid 32005030)
40. Rao VK, Price S, Perkins K, et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 2009; 52:847-852.
41. Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 2009; 146:120-122.
42. Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood 2011. [Epub ahead of print] This article establishes the risk of postsplenectomy sepsis in ALPS.
43. Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 2011; 118:4798-4807. This article establishes the risk of postsplenectomy sepsis in ALPS.
44. Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005; 129:534-538. (Pubitemid 40769903)
45. Izeradjene K, Quemeneur L, Michallet MC, et al. Mycophenolate mofetil interferes with interferon gamma production in T-cell activation models. Transplant Proc 2001; 33:2110-2111. (Pubitemid 33762650)
46. Pizon M, Rampanarivo H, Tauzin SB, Chaigne-Delalande B, et al. PI3K/AKT inhibition elicits actin-independent and CD95-dependent apoptotic signaling through localisation of CD95 into lipid rafts. Eur J Immunol 2011; 41:2368-2378.
47. Mittal SK, Sharma RK, Gupta A, Naik S. Increased interleukin-10 production without expansion of CD4CD25 T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. Transplantation 2009; 88:435-441.
48. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765. (Pubitemid 32368050)
49. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90:770-774. (Pubitemid 23028947)
50. Baker AK, Wang R, Mackman N, Luyendyk JP. Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. Mol Immunol 2009; 46: 2249-2255.
51. Weichhart T, Saemann MD. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 2008; 67 (Suppl. 3):iii70-iii74.
52. Kossiva L, Theodoridou M, Mostrou G, et al. Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome. J Pediatr Hematol Oncol 2006; 28:824-826. (Pubitemid 44967678)
53. Teachey DT, Obzut DA, Axsom K, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 2006; 108:1965-1971. (Pubitemid 44395007)
54. Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 2009; 145:101-106.
55. Teachey DT. Autoimmune lymphoproliferative syndrome: new approaches to diagnosis and management. Clin Adv Hematol Oncol 2011; 9:233-235.
56. Janic MD, Brasanac CD, Jankovic JS, et al. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer 2009; 53:1117-1119.
57. Tommasini A, Valencic E, Piscianz E, Rabusin M. Immunomodulatory drugs in autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 2011. [Epub ahead of print]
58. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007; 82: 381-388. (Pubitemid 47414349)